Dr Tanzina Haque

Job title

Clinical lead consultant virologist and honorary senior lecturer



Contact details

Email address: thaque@nhs.net

PA/secretary phone number: 020 7317 7521

Fax: 020 7317 7657

Related services



Dr Haque is a consultant virologist and an honorary senior lecturer with an interest in pathogenesis and treatment of viral infections in immunocompromised patients, in particular transplant patients, EBV and PTLD. Other areas of interests are viral hepatitis, prevention and management of blood-borne virus infections in dialysis, emerging infections.


  • Akay E, Patel M, Conibear T, Chaggar T, Haque T. (2014). Interleukin (IL) 28B gene polymorphisms and Epstein-Barr virus-associated lymphoproliferative diseases. Intervirology. 57:112-115
  • McCormick A, Wang L, Garcia-Diaz A, Macartney M, Webster D and Haque T. (2014). Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug naïve individuals with hepatitis C genotypes 1-4. Antiviral Therapy. Published online. DOI: 10.3851/IMP2763
  • Macartney M, Irish D, Bridge S, Garcia A, Booth C, McCormick A, Labbett W, Smith C, Velazquez C, Tanwar S, Trembling P, Jacobs M, Dusheiko G, Rosenberg W, Haque T. (2014). Telaprevir or boceprevir based therapy chronic hepatitis C infection: Development of resistance-associated variants is a major cause of treatment failure. Antiviral Research. 105: 112–117
  • Guerrero-Ramos A, Patel M, Kadakia K and Haque T. (2014).  Performance of the ARCHITECT EBV serology panel for the determination of Epstein-Barr virus serological status in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis. Clinical Vaccine and Immunology. 21 (6): 817-823
  • Haywood B, Patel M, Hurday S, Coping R, Webster D, Irish D, Haque T. (2014). Comparison of automated chemiluminescence immunoassays with capture enzyme immunoassays for the detection of measles and mumps IgM antibodies in serum. Journal of Virological Methods. 196:15 - 17 
  • Halliday N, Smith C, Aitkinson C, Patch D, Burroughs A, Thorburn D, Haque T. (2014). Characteristics of Epstein-Barr viraemia in adult orthotopic liver transplant patients. A retrospective cohort study. Transplant International. Published online. doi: 10.1111/tri.12342
  • Hyams C, Mabayoje D, Copping R, Maraneo D, Patel M, Labbett W, Haque T, Webster D. (2014). Cross reactivity to CMV and EBV causing problems in the serological diagnosis of acute hepatitis E virus infection. Journal of Medical Virology. 86(3):478-83.
  • Garcia-Diaz A, Guerrero-Ramos A, McCormick AL, Macartney M, Conibear T, Johnson MA, Haque T and Webster DP (2013). Evaluation of the Roche Prototype 454 HIV-1 Ultradeep Sequencing Drug Resistance Assay in a Routine Diagnostic Laboratory. Journal of Clinical Virology. 58(2):468-73.
  • Haque T, Chaggar T, Schafers J, Atkinson C, McAulay KA, Crawford DH. (2011). Soluble CD30: A serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. Journal of Medical Virology. 83(2):311-6
  • Johannessen I, Bieleski L, Urquhart G, Watson SL, Wingate P, Haque T, Crawford DH. (2011). Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo. Journal of Medical Viroliology. 83(9):1585-96.
  • Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O’Beirne J, Thorburn D,  Patch D, Emery VC, Milne R, Atkinson C, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Burroughs AK. (2011). A Randomised Placebo Controlled Pharmacodynamic Trial of Cytomegalovirus Glycoprotein B Vaccine with MF59 Adjuvant in Transplant Patients. The Lancet. 377(9773):1256-1263.
  • Haque T, McAulay KA, Kelly D, Crawford DH (2010). Allogeneic T cell therapy for EBV-positive post-transplant lymphoproliferative disease (PTLD): Long-term follow-up. Transplantation. 90(1):93-4
  • Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis P, Griffiths P, Mackinnon S and Chakraverty R. (2010). Epstein-Barr virus reactivation following Alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation. 90(5): 564-570.
  • McAulay KA, Haque T, Urquhart G, Bellamy C, Guiretti D, Crawford DH (2009). Epitope Specificity and Clonality of EBV-specific Cytotoxic T-Lymphocytes used to Treat Post Transplant Lymphoproliferative Disease. Journal of Immunology, 182(6):3892-3901. 
  • Holmes M, Caplin B, Atkinson C, Smith C, Harber M, Sweny P, Haque T (2009). Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early post-transplant period: role of mycophenolate mofetil. Transplantation, 87(6): 852-856.
  • Vanhoutte VJ, McAulay KA, Mccarrell E, Turner M, Crawford DH, Haque T (2009). Cytolytic Mechanisms and T Cell Receptor Vβ Usage by Ex Vivo Generated EBV-Specific Cytotoxic T Lymphocytes. Immunology, 127(4): 577-586.
  • McAulay KA, Haque T, Crawford DH (2009). Tumour necrosis factor gene polymorphism: a possible predictive factor for the development of post-transplant lymphoproliferative disease. British Journal of Cancer. 101(6):1019-27
  • Haque T, Wilkie G, Higgins C, Jones M, Urquhart G, Wingate P, Burns D, McAulay K, Bellamy C, Turner M, Amlot P, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH. (2007). Allogeneic cytotoxic T cell therapy for EBV-positive post transplant lymphoproliferative disease: Results of a phase II multicentre clinical trial. Blood, 110: 1123-1131
  • Haque T, Johannessen I, Dambogoda D, Sengupta C, Burns D, Hale G, Bird P, Mieli-Vergani G, Crawford DH. (2006). 72A1, a mouse monoclonal antibody against EBV envelop glycoprotein gp350 prevents EBV infection in vitro and in vivo. Journal of Infectious Diseases. 194: 584-587 
  • Wynn R, Arkwright P, Haque T, Gharib M, Wilkie G, Jones M, Crawford D (2005). Successful treatment of an Epstein-Barr virus (EBV)-driven primary CNS B cell lymphoma with allogeneic T cell immunotherapy and stem cell transplantation. Lancet Oncology. 6 (5): 344-346.
  • Battegay M, Berger C, Rochlitz C, Hurwitz N, Hirsch H, Haque T, Nadal D. (2004). EBV-associated angio-immunoblastic lymphoma in an immunocompetent woman. Antiviral Therapy. 9: 453-459. 
  • Wilkie G, Taylor C, Jones M, Burns D, Turner M, Kilpatrick D, Amlot P, Tahami F, Britton K, Crawford DH, Haque T. (2004). Establishment and characterisation of a bank of CTL for immunotherapy of EBV-associated diseases. Journal of Immunotherapy. 27: 309-316.
  • Haque T, Wilkie W, Taylor C, Amlot P, Murad P, Iley A, Dombagoda D, Britton K, Swerdlow A, Crawford DH (2002). Treatment of EBV-positive post transplant lymphoproliferative disease (PTLD) using partially HLA-matched allogeneic cytotoxic T cells. Lancet. 360: 436-442.
  • Longhurst H, Taussig D, Haque T, Court D, Cavenagh J, Edgar J, Helbert M. (2002). Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich Syndrome (WAS). British Journal of Haematology 116: 497-499.
  • Haque T, Taylor C, Wilkie G, Murad P, Amlot P, Beath S, McKiernan P, Crawford DH. (2001). Complete regression of PTLD using partially HLA-matched EBV-specific cytotoxic T cells. Transplantation 72: 1399-1402.